Roggwil, November 12, 2020 – The study on tinniwell agreed with the Charité in Berlin cannot currently be started due to the pandemic situation. There is currently still no return to unrestricted face-to-face research. As soon as the study can be started, we will publish it here immediately.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016. Resaphene Deutschland GmbH in Constance, Resaphene UK Ltd. act as further sales companies in London and Resaphene US LLC in the US.
++ Contact for questions:
Resaphene Suisse AG
Mrs. Anke Rauterkus (Chief Executive Officer)
T. +41 714500668